GlassScriptPhysician profile
Nomita Joshi
NPI 1104865575
$5,307.54
in general payments reported to CMS, 2019-2025
28 companies · $412 in 2025
The $412 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $568 · 2020: $704 · 2021: $1,228 · 2022: $601 · 2023: $792 · 2024: $1,003 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,206.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $706.71 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $663.41 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $642.24 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $528.28 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $348.71 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $339.54 | 2021-2025 | |
| Glaxosmithkline, LLC. | $268.24 | 2020-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $232.53 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $193.84 | 2024-2025 | Voquezna |
| Abbott Laboratories | $184.63 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Allergan, INC. | $170.73 | 2019-2020 | |
| Amarin Pharma, INC. | $139.87 | 2019-2021 | |
| Daiichi Sankyo INC. | $123.72 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $108.94 | 2024 | Rexulti |
| Lundbeck LLC | $101.43 | 2023-2024 | Rexulti |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $87.35 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $78.11 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.75 | 2021-2022 | |
| Exact Sciences Corporation | $55.75 | 2023-2024 | Cologuard Collection Kit |
| Eisai INC. | $49.45 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $46.12 | 2021-2023 | |
| Amgen INC. | $45.35 | 2019-2025 | Repatha |
| Astellas Pharma US INC | $34.73 | 2020-2023 | Veozah |
| Insmed, INC. | $20.78 | 2022 | |
| Ardelyx, INC. | $20.53 | 2025 | Ibsrela |
| Currax Pharmaceuticals LLC | $14.85 | 2021 | |
| Azurity Pharmaceuticals, INC. | $14.30 | 2023 | Edarbi |
| Dexcom, INC. | $13.65 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nomita Joshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.